FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to application of an isolated antibody to CXCR4 in the diagnosis of cancer, which can be used in medicine. In particular, methods for diagnosis and/or prediction of an oncogenic disorder associated with CXCR4 expression, determination whether the disorder or treated patient are susceptible to treatment with an anti-CXCR4 antibody, methods for determination of an effective treatment regimen, and kits for treatment of the said diseases are disclosed.
EFFECT: invention allows effective diagnosis and therapy of oncogenic disorders characterized by CXCR4 expression.
18 cl, 7 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTIBODY TO CXCR4 AND ITS APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636345C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| ANTI-CXCR4 ANTIBODIES FOR TREATMENT OF HIV INFECTION | 2010 |
|
RU2573902C2 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706959C2 |
| IGF-1R ANTIBODY AND USE THEREOF FOR DIAGNOSING CANCER | 2016 |
|
RU2706967C2 |
| COMPOSITIONS CONTAINING ANTI-SEAMS 1 AND ANTI-PD ANTIBODIES FOR CANCER THERAPY | 2014 |
|
RU2697522C1 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND APPLICATION THEREOF | 2017 |
|
RU2793445C2 |
